{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-047119","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.285727+00:00","generated_at":"2026-05-30T02:18:25.172688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prime Medicine Q3 net loss $52.5M; BMS collaboration provides $110M upfront","bullets":["Net loss of $52.5M in Q3 2024 vs. $50.7M in Q3 2023; R&D expenses $40.3M, G&A $14.1M.","Pro-forma cash $244.6M, sufficient to fund operations into 1H 2026.","Entered strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies; $110M upfront (including $55M equity investment), potential milestones >$3.5B.","Wilson's Disease program initiated IND-enabling activities; IND/CTA filing expected 1H 2026.","Phase 1/2 trial of PM359 for p47 phox CGD ongoing; initial clinical data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-047119","json":"https://secwatch.observer/filing/0001628280-24-047119.json","markdown":"https://secwatch.observer/filing/0001628280-24-047119.md","text":"https://secwatch.observer/filing/0001628280-24-047119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024047119/0001628280-24-047119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024047119/prme-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:18:25.172688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}